Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating

Key Points

• Wall Street Zen upgraded Haemonetics to “strong buy” from “buy.” Overall analyst sentiment is “Moderate Buy,” with a consensus price target of $90.89.
• Haemonetics exceeded quarterly expectations, reporting $1.14 EPS versus $1.08 expected and $339.38 million in revenue, up 5.5% year over year. Management also raised its fiscal 2027 revenue-growth outlook to approximately 5%–8%.
• The stock opened at $87.50, near its 12-month high of $88.58, while BTIG raised its price target to $96 and maintained a “buy” rating.

Haemonetics (NYSE:HAE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Saturday.

A number of other analysts have also recently issued reports on the company. Weiss Ratings raised Haemonetics from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, June 25th. Mizuho upped their target price on Haemonetics from $85.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Barrington Research set a $95.00 price target on Haemonetics in a research note on Friday. BTIG Research lifted their price target on Haemonetics from $84.00 to $96.00 and gave the company a "buy" rating in a report on Thursday. Finally, Bank of America raised Haemonetics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $90.89.

Haemonetics Stock Up 2.9%

Haemonetics stock opened at $87.50 on Friday. Haemonetics has a twelve month low of $47.31 and a twelve month high of $88.58. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.87 and a current ratio of 3.08. The firm has a market cap of $3.98 billion, a PE ratio of 42.89, a P/E/G ratio of 1.71 and a beta of 0.52. The firm's 50 day moving average price is $76.98 and its two-hundred day moving average price is $66.52.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. During the same quarter last year, the business posted $1.10 EPS. The company's revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts predict that Haemonetics will post 5.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors have recently bought and sold shares of the stock. North Peak Capital Management LLC grew its position in shares of Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier's stock valued at $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Aurora Investment Counsel bought a new stake in Haemonetics during the 1st quarter valued at approximately $1,217,000. London Co. of Virginia grew its holdings in Haemonetics by 33.9% in the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier's stock valued at $19,884,000 after buying an additional 89,242 shares during the last quarter. Strs Ohio bought a new position in Haemonetics in the 4th quarter worth approximately $986,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier's stock worth $74,731,000 after buying an additional 233,119 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source